Keros Therapeuticsinc Stock Fundamentals
| KROS Stock | USD 46.87 0.56 1.21% |
Keros TherapeuticsInc fundamentals help investors to digest information that contributes to Keros TherapeuticsInc's financial success or failures. It also enables traders to predict the movement of Keros Stock. The fundamental analysis module provides a way to measure Keros TherapeuticsInc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Keros TherapeuticsInc stock.
At this time, Keros TherapeuticsInc's Net Interest Income is comparatively stable compared to the past year. Other Operating Expenses is likely to gain to about 176.1 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 774.2 K in 2024. Keros | Select Account or Indicator |
Keros TherapeuticsInc Company Return On Asset Analysis
Keros TherapeuticsInc's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Keros TherapeuticsInc Return On Asset | -0.26 |
Most of Keros TherapeuticsInc's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Keros TherapeuticsInc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Keros Total Assets
Total Assets |
|
Based on the latest financial disclosure, Keros TherapeuticsInc has a Return On Asset of -0.2579. This is 97.05% lower than that of the Biotechnology sector and 98.91% lower than that of the Health Care industry. The return on asset for all United States stocks is 84.21% higher than that of the company.
Keros TherapeuticsInc Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Keros TherapeuticsInc's current stock value. Our valuation model uses many indicators to compare Keros TherapeuticsInc value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Keros TherapeuticsInc competition to find correlations between indicators driving Keros TherapeuticsInc's intrinsic value. More Info.Keros TherapeuticsInc is currently regarded as number one stock in return on equity category among related companies. It is currently regarded as number one stock in return on asset category among related companies . At this time, Keros TherapeuticsInc's Return On Equity is comparatively stable compared to the past year.Comparative valuation analysis is a catch-all model that can be used if you cannot value Keros TherapeuticsInc by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Keros TherapeuticsInc's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Keros TherapeuticsInc's earnings, one of the primary drivers of an investment's value.Keros Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Keros TherapeuticsInc's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Keros TherapeuticsInc could also be used in its relative valuation, which is a method of valuing Keros TherapeuticsInc by comparing valuation metrics of similar companies.Keros TherapeuticsInc is currently under evaluation in return on asset category among related companies.
Keros TherapeuticsInc Current Valuation Drivers
We derive many important indicators used in calculating different scores of Keros TherapeuticsInc from analyzing Keros TherapeuticsInc's financial statements. These drivers represent accounts that assess Keros TherapeuticsInc's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Keros TherapeuticsInc's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Enterprise Value | 172.6M | 828.8M | 1.1B | 946.3M | 854.1M | 545.9M |
Keros TherapeuticsInc ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Keros TherapeuticsInc's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Keros TherapeuticsInc's managers, analysts, and investors.Environmental | Governance | Social |
Keros Fundamentals
| Return On Equity | -0.4 | ||||
| Return On Asset | -0.26 | ||||
| Operating Margin | (584.13) % | ||||
| Current Valuation | 1.26 B | ||||
| Shares Outstanding | 36.08 M | ||||
| Shares Owned By Insiders | 6.36 % | ||||
| Shares Owned By Institutions | 93.64 % | ||||
| Number Of Shares Shorted | 2.43 M | ||||
| Price To Book | 6.36 X | ||||
| Price To Sales | 13,966 X | ||||
| Revenue | 151 K | ||||
| Gross Profit | (87.27 M) | ||||
| EBITDA | (166.93 M) | ||||
| Net Income | (152.99 M) | ||||
| Cash And Equivalents | 215.62 M | ||||
| Cash Per Share | 8.37 X | ||||
| Total Debt | 14.44 M | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 14.39 X | ||||
| Book Value Per Share | 12.59 X | ||||
| Cash Flow From Operations | (124.51 M) | ||||
| Short Ratio | 8.20 X | ||||
| Earnings Per Share | (5.15) X | ||||
| Target Price | 90.63 | ||||
| Number Of Employees | 141 | ||||
| Beta | 1.32 | ||||
| Market Capitalization | 1.69 B | ||||
| Total Asset | 370.02 M | ||||
| Retained Earnings | (381.43 M) | ||||
| Working Capital | 322.92 M | ||||
| Current Asset | 11.95 M | ||||
| Current Liabilities | 5.72 M | ||||
| Net Asset | 370.02 M |
About Keros TherapeuticsInc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Keros TherapeuticsInc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Keros TherapeuticsInc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Keros TherapeuticsInc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 19.8 M | 20.8 M | |
| Total Revenue | 151 K | 143.4 K | |
| Cost Of Revenue | 815 K | 774.2 K | |
| Stock Based Compensation To Revenue | 171.44 | 180.01 | |
| Sales General And Administrative To Revenue | 207.62 | 218.00 | |
| Research And Ddevelopement To Revenue | 806.17 | 846.48 | |
| Capex To Revenue | (18.77) | (17.83) | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | -1.3 K | -1.2 K |
Pair Trading with Keros TherapeuticsInc
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Keros TherapeuticsInc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Keros TherapeuticsInc will appreciate offsetting losses from the drop in the long position's value.Moving together with Keros Stock
| 0.89 | EQ | Equillium | PairCorr |
Moving against Keros Stock
| 0.66 | VALN | Valneva SE ADR | PairCorr |
The ability to find closely correlated positions to Keros TherapeuticsInc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Keros TherapeuticsInc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Keros TherapeuticsInc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Keros TherapeuticsInc to buy it.
The correlation of Keros TherapeuticsInc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Keros TherapeuticsInc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Keros TherapeuticsInc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Keros TherapeuticsInc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Keros TherapeuticsInc Piotroski F Score and Keros TherapeuticsInc Altman Z Score analysis. For more information on how to buy Keros Stock please use our How to Invest in Keros TherapeuticsInc guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for Keros Stock analysis
When running Keros TherapeuticsInc's price analysis, check to measure Keros TherapeuticsInc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros TherapeuticsInc is operating at the current time. Most of Keros TherapeuticsInc's value examination focuses on studying past and present price action to predict the probability of Keros TherapeuticsInc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros TherapeuticsInc's price. Additionally, you may evaluate how the addition of Keros TherapeuticsInc to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |
Is Keros TherapeuticsInc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Keros TherapeuticsInc. If investors know Keros will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Keros TherapeuticsInc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.15) | Revenue Per Share 0.007 | Return On Assets (0.26) | Return On Equity (0.40) |
The market value of Keros TherapeuticsInc is measured differently than its book value, which is the value of Keros that is recorded on the company's balance sheet. Investors also form their own opinion of Keros TherapeuticsInc's value that differs from its market value or its book value, called intrinsic value, which is Keros TherapeuticsInc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Keros TherapeuticsInc's market value can be influenced by many factors that don't directly affect Keros TherapeuticsInc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Keros TherapeuticsInc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Keros TherapeuticsInc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Keros TherapeuticsInc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.